Knight Therapeutics (GUD.TO)

Knight Therapeutics (GUD-T) has garnered mixed reviews from experts who see both potential and challenges in the company's trajectory. The company's strategy of acquiring orphaned drugs offers a unique business model; however, there is a prevailing concern about the consistency of earnings, which is crucial for maintaining investor confidence. Experts suggest that while the stock appears to be cheap, historical performance indicates a lack of steady upward movement, often leading investors to feel as though they might lose out over time. Current trading levels around $5.75 to $6 are critical, with predictions that if these levels can't be maintained, the stock may retreat to $5.14. Despite some positive indicators like expanding margins and operational success in Brazil, investors may need to exercise patience as the stock undergoes general market volatility.